{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:39:37Z","timestamp":1770741577388,"version":"3.49.0"},"reference-count":7,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In view of the role of pharmacotherapy in medicine, on the one hand, and the powerful technical possibilities that are now available on the other hand, therapeutic drug monitoring is a surprisingly neglected area of laboratory medicine. In this viewpoint article, an \u201comics approach\u201d to pharmacovigilance and drug monitoring is proposed and discussed. A realistic goal for laboratory medicine in the 21st century should indeed be to enable clinicians to check whether the right drug is present in the right patient with an appropriate blood concentration for each compound.<\/jats:p>","DOI":"10.1515\/cclm-2020-0339","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T17:10:01Z","timestamp":1590513001000},"page":"287-290","source":"Crossref","is-referenced-by-count":11,"title":["From therapeutic drug monitoring to total drug monitoring and drug-omics"],"prefix":"10.1515","volume":"59","author":[{"given":"Michael","family":"Vogeser","sequence":"first","affiliation":[{"name":"Institute of Laboratory Medicine , Hospital of the University of Munich (LMU) , Marchioninistr. 15 , 81377 Munich , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2023033111461499060_j_cclm-2020-0339_ref_001_w2aab3b7c34b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Vogeser M, Zhang V. Understanding the strategic landscape surrounding the implementation of mass spectrometry in the clinical laboratory: a SWOT analysis. Clin Mass Spectrom 2018;9:1\u20136.","DOI":"10.1016\/j.clinms.2018.06.001"},{"key":"2023033111461499060_j_cclm-2020-0339_ref_002_w2aab3b7c34b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Wong JW, Wang J, Zhan K, Hayward G, Wittenberg JG. Pesticides: an update on mass spectrometry approaches. In: Encyclopedia Food Chemistry. Amsterdam, The Netherlands: Elsevier, 2019:433\u20138.","DOI":"10.1016\/B978-0-08-100596-5.21813-1"},{"key":"2023033111461499060_j_cclm-2020-0339_ref_003_w2aab3b7c34b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Zander J, Paal M, Vogeser M. The role of mass spectrometry in antibiotic stewardship. Clin Mass Spectrom 2019;14:31\u20133.","DOI":"10.1016\/j.clinms.2018.11.001"},{"key":"2023033111461499060_j_cclm-2020-0339_ref_004_w2aab3b7c34b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2019;10:1662.","DOI":"10.3389\/fphar.2019.01662"},{"key":"2023033111461499060_j_cclm-2020-0339_ref_005_w2aab3b7c34b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4\/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 2019;21:25.","DOI":"10.1007\/s11912-019-0769-3"},{"key":"2023033111461499060_j_cclm-2020-0339_ref_006_w2aab3b7c34b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Verheijen RB, Huixin Y, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 2017;102:765\u201376.","DOI":"10.1002\/cpt.787"},{"key":"2023033111461499060_j_cclm-2020-0339_ref_007_w2aab3b7c34b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Benton SC, Tetteh GK, Needham SJ, M\u00fccke J, Sheppard L, Alderson S, et al. Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory. Clin Chem Lab Med 2020;58:1010\u20137.","DOI":"10.1515\/cclm-2019-0834"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/59\/2\/article-p287.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0339\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T15:43:20Z","timestamp":1680277400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-0339\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,2]]},"published-print":{"date-parts":[[2021,2,23]]}},"alternative-id":["10.1515\/cclm-2020-0339"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2020-0339","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,5]]}}}